|
Biopharmaceutical Manufacturing
|
US$
300 |
|
May-2025 |
Doc #42255 |
|
| Printed Page Length :
20
pages |
| Number of Tables :
3 |
| Number of Figures:
2 |
|
Market Overview
|
|
The launch of certain Taiwanese-developed biological and biosimilar drugs in the U.S. market has faced delays, primarily due to reduced staffing at pharmaceutical regulatory agencies under the Trump administration. This, combined with persistent weakness in China's self-funded vaccine market, has intensified pressure on Taiwanese manufacturers seeking to expand their U.S. market presence. Nevertheless, overseas sales are expected to remain supported by the continued performance of domestically developed, special-indication biological drugs—such as PharmaEssentia Corporation’s Ropeg and Tanvex BioPharma Inc’s Nypozi—which have already entered international markets. Additionally, Taiwan’s public vaccine procurement volume is projected to rise in 2025 compared to 2024, further supporting domestic demand.
|
|
|
|